Loading...
01/10 05:39
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong revenue growth for both Revuforj and Niktimvo, with positive physician and patient feedback. The company expects profitability with existing resources and stable expenses. The Q&A section provides confidence in FDA approval and market expansion, particularly with the NPM1 label expansion. Although management avoided specific guidance, the overall sentiment is positive with strong financial performance and optimistic future outlooks.
Combined net product sales (Revuforj and Niktimvo) Nearly $100 million in the first half of 2025, significantly exceeding expectations.
Revuforj net revenue $28.6 million in Q2 2025, a 43% quarter-over-quarter increase. Growth attributed to strong uptake, high unmet medical need, and physician enthusiasm.
Niktimvo net revenue $36.2 million in Q2 2025, up from $13.6 million in the first 2 months of Q1. Growth attributed to strong demand and positive physician and patient feedback.
Niktimvo collaboration revenue to Syndax $9.4 million in Q2 2025. Niktimvo is already profitable to Syndax.
R&D expense $62.2 million in Q2 2025, increased due to ongoing trials and commercialization support.
SG&A expense $43.8 million in Q2 2025, increased due to U.S. commercial launch of Revuforj.
Cash, equivalents, and investments $518 million as of June 30, 2025. Expected to support profitability without additional funding.
Revuforj and Niktimvo sales: Combined net product sales reached nearly $100 million in the first half of 2025, exceeding expectations. Revuforj net revenue increased 43% quarter-over-quarter to $28.6 million.
Revuforj FDA approval: Revuforj is the first and only FDA-approved treatment for relapsed or refractory acute leukemia with a KMT2A translocation.
Niktimvo launch: Niktimvo generated $36.2 million in net revenue in Q2 2025, up from $13.6 million in Q1.
Market opportunity for Revuforj: The combined market opportunity for Revuforj and Niktimvo exceeds $10 billion. Revuforj's U.S. relapsed/refractory market opportunity is $2 billion, with potential expansion to a $5 billion frontline market.
Market opportunity for Niktimvo: Niktimvo targets a $2 billion total addressable market in third-line chronic GVHD treatments.
Operational efficiency: Operating expenses are expected to remain stable over the next few years, while fully funding strategic priorities. Syndax expects to reach profitability with current funds on hand.
Patient identification and treatment: Over 500 patients have been treated with Revuforj since launch, with 90% of usage in KMT2A patients. Revuforj is increasingly used in earlier lines of therapy, improving outcomes.
Strategic leadership in menin space: Syndax aims to expand Revuforj into earlier lines of therapy and additional patient populations, including frontline settings.
Niktimvo development: Niktimvo is being developed for additional patient populations and diseases, including idiopathic pulmonary fibrosis (IPF).
Regulatory Approval Risks: The company is awaiting FDA approval for its supplemental new drug application (sNDA) for Revuforj in relapsed/refractory mutant NPM1 AML. Any delays or rejections could impact the expansion of their addressable market and revenue projections.
Market Competition: Revuforj and Niktimvo face potential competition from 'me-too' competitors and other targeted therapies in their respective markets. This could impact market share and revenue growth.
Supply Chain and Manufacturing Risks: The company did not explicitly mention supply chain issues, but any disruptions in manufacturing or distribution could impact product availability and sales.
Economic and Market Conditions: Economic uncertainties or changes in healthcare reimbursement policies could affect the affordability and accessibility of the company's therapies, impacting sales.
Clinical Trial Risks: Ongoing and planned clinical trials for Revuforj and Niktimvo in new indications and earlier lines of therapy carry risks of failure or delays, which could hinder market expansion and revenue growth.
Physician and Patient Adoption: While initial adoption of Revuforj and Niktimvo has been strong, sustained growth depends on continued physician and patient acceptance, which could be influenced by emerging data or competitive products.
Financial Risks: The company is relying on its current cash reserves and revenue from two products to achieve profitability. Any underperformance in sales or unexpected expenses could strain financial resources.
Revenue Growth: The company expects quarterly revenue growth to accelerate meaningfully over the next year, driven by the potential approval of Revuforj in NPM1 and longer treatment durations in KMT2Ar acute leukemia.
Revuforj Expansion: Revuforj is expected to expand into relapsed/refractory mutant NPM1 AML, pending FDA approval of the sNDA with a PDUFA action date of October 25, 2025. This expansion could increase the U.S. market opportunity to $2 billion.
Frontline Market Opportunity: The company is extending its leadership position into the frontline setting for acute leukemia, a U.S. market opportunity exceeding $5 billion. Enrollment is ongoing in pivotal trials for patients unfit for intensive chemotherapy, with additional trials for fit patients expected to start in Q4 2025.
Niktimvo Growth: Niktimvo is poised for further growth in the $2 billion third-line chronic GVHD market. The company anticipates long-term patient retention on therapy due to the chronic nature of the disease and the drug's tolerability.
Profitability Outlook: Syndax expects to achieve sustained profitability with current funds on hand, driven by increasing cash flow contributions from Revuforj and Niktimvo alongside a stable operating expense base.
Pipeline Development: The company is advancing trials for Revuforj in newly diagnosed fit and unfit acute leukemia patients, as well as for Niktimvo in earlier lines of chronic GVHD therapy and idiopathic pulmonary fibrosis (IPF).
Market Penetration: Revuforj aims to penetrate 50% of the annual 2,000 patient incidence for KMT2A acute leukemia by the end of 2025, with increasing use in earlier treatment lines and post-transplant settings.
The selected topic was not discussed during the call.
The earnings call summary highlights strong financial performance, product development, and market strategy, with optimistic guidance and shareholder return plans. The Q&A section provides additional positive insights, such as excellent payer access and a consistent safety profile for Revuforj. The strategic plan indicates significant growth opportunities, including market expansion and profitability outlook. Considering the company's strong market position, upcoming product approvals, and positive financial health, the stock is likely to see a positive movement in the short term.
The earnings call highlights strong revenue growth for both Revuforj and Niktimvo, with positive physician and patient feedback. The company expects profitability with existing resources and stable expenses. The Q&A section provides confidence in FDA approval and market expansion, particularly with the NPM1 label expansion. Although management avoided specific guidance, the overall sentiment is positive with strong financial performance and optimistic future outlooks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
